🇺🇸 FDA

Drug profile · INN

glatiramer acetate

GLATOPA

approved
US status
approved
Patents linked
8
News articles
0

Quick answer

glatiramer acetate (GLATOPA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.

Key facts

INN glatiramer acetate
Brand GLATOPA
Route SUBCUTANEOUS
Formulation INJECTABLE
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 9763993

    Process for manufacturing glatiramer acetate product

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9702007

    Genetic markers predictive of response to glatiramer acetate

    Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9687522

    Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9625473

    Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9617596

    Biomarkers predictive for clinical response for glatiramer acetate

    Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9499868

    Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9155775

    Process for manufacturing glatiramer acetate product

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9063153

    Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is glatiramer acetate?

glatiramer acetate (GLATOPA) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.

What is the brand name for glatiramer acetate?

GLATOPA is a marketed brand name for glatiramer acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of glatiramer acetate?

glatiramer acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.